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Abstract
Leishmaniasis is a vector borne disease caused by protozoa of the genus Leishmania.
Human leishmaniasis is not endemic in Australia though imported cases are regularly en-
countered. This study aimed to provide an update on the molecular epidemiology of im-
ported leishmaniasis in Australia. Of a total of 206 biopsies and bone marrow specimens
submitted to St Vincent’s Hospital Sydney for leishmaniasis diagnosis by PCR, 55 were
found to be positive for Leishmania DNA. All PCR products were subjected to restriction
fragment length polymorphism analysis for identification of the causative species. Five
Leishmania species/species complexes were identified with Leishmania tropica being the
most common (30/55). Travel or prior residence in a Leishmania endemic region was the
most common route of acquisition with ~47% of patients having lived in or travelled to Af-
ghanistan. Cutaneous leishmaniasis was the most common manifestation (94%) with only 3
cases of visceral leishmaniasis and no cases of mucocutaneous leishmaniasis encoun-
tered. This report indicates that imported leishmaniasis is becoming increasingly common
in Australia due to an increase in global travel and immigration. As such, Australian clini-
cians must be made aware of this trend and consider leishmaniasis in patients with suspi-
cious symptoms and a history of travel in endemic areas. This study also discusses the
recent identification of a unique Leishmania species found in native kangaroos and a poten-
tial vector host which could create the opportunity for the establishment of a local transmis-
sion cycle within humans.
Introduction
Leishmaniasis is a vector-borne disease caused by protozoa of the genus Leishmania. The dis-
ease is transmitted via sand flies of the genus Phlebotomus in the old world (Europe, Asia and
Africa) and Lutzomyia in the new world (the Americas) [1]. There are over 14 species of
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Leishmania which may cause up to three different clinical syndromes [2,3]: cutaneous leish-
maniasis (CL) manifests as ulcerated skin lesions; mucocutaneous leishmaniasis (MCL) affects
the mucous membranes of the nose, mouth and throat and can lead to partial or total destruc-
tion of the associated membranes; and visceral leishmaniasis (VL) is a systemic, potentially le-
thal disease caused by parasites of the Leishmania donovanii complex [4,5]. There are an
estimated 1.2 million cases of CL and 400,000 cases of VL reported annually worldwide [6],
while MCL is a much rarer illness. In Australia leishmaniasis is an imported disease with no lo-
cally acquired human infections described to date. Imported cases of leishmaniasis are becom-
ing increasingly common in non-endemic regions such as Australia, North America and
Northern Europe, due to increased international travel, immigration and deployment of de-
fence personnel to endemic areas [5,7,8]. There are several clinically important Leishmania sp.
and each are morphologically indistinguishable. Whilst a patient’s travel history may facilitate
determination of the causative species, different species often occupy overlapping geographic
ranges [5]. As the response to treatment in clinical cases of leishmaniasis may be species specif-
ic [9], accurate speciation is important to determine optimal treatment and precise prognosis.
The life cycle of Leishmania sp. is a two-stage cycle involving a vertebrate host and an insect
vector. During this cycle, the parasite exists in two different morphological states: as amasti-
gotes inside phagocytes of their vertebrate hosts, or as flagellated promastigotes within the gut
of their insect vector, usually a phlebotamine sand fly [10]. Within its endemic range, leish-
maniasis is a common zoonoses and infects a variety of animals including feral dogs, marsupi-
als, rodents and domestic animals [3,11]. Until recently Australia was thought to be free of
leishmaniasis though with the confirmation of CL in native Australian macropods, Antarctica
is now the only continent thought to be Leishmania free [12,13]. The discovery of a native spe-
cies of Leishmania in Australia raises two important queries; (1) whether this native Leishman-
ia sp. has the capacity to cause human disease under certain circumstances, and (2) whether
the proposed native Australian insect vector has the capacity to transmit other, clinically im-
portant Leishmania sp.
Over the last decade the number of cases of imported leishmaniasis has doubled in the
Netherlands and tripled in the UK [14].There are few recent reports describing imported cases
of leishmaniasis in Australia [15–20] and as a consequence, current data on the molecular epi-
demiology of Australian imported leishmaniasis is lacking. Furthermore, with the increase in
global travel, immigration to Australia, and the despatch of Australian military personnel to
endemic regions, it is important that the current status of leishmaniasis in Australia is regularly
monitored. Therefore, the aim of this study was to provide a current, large-scale report on the
molecular epidemiology of imported leishmaniasis in Australia.
Materials and Methods
A total of 206 punch biopsies or bone marrow aspirates from patients with suspected leishman-
iasis infection were submitted to the Department of Microbiology, St. Vincent’s Hospital, Syd-
ney, Australia between July 2008 and March 2014. DNA was extracted from all tissue samples
using a Qiagen Tissue extraction kit (Qiagen, Hilden, Germany) and the Qiagen Biorobot EZ1.
The DNA extracts were used as template for a conventional PCR assay targeting the ITS1 re-
gion of Leishmania sp., which has been previously described [21]. A portion of all PCR prod-
ucts was subjected to agarose gel electrophoresis on a 2% agarose gel (Life Technologies). Gels
were visualised under UV light to confirm the presence of a PCR product from 300–350bp
in size, which is indicative of a Leishmania positive sample. Confirmation of the causative
Leishmania species was carried out on all PCR positive samples by restriction fragment length
polymorphism (RFLP) analysis. For RFLP analysis, PCR products were digested using the
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restriction enzymeHaeIII (as per [7]). Digestion was carried out for 60 minutes using the con-
ditions recommended by the supplier (Sigma-Aldrich). Restriction fragments were then sub-
jected to agarose gel electrophoresis on a 4% gel (Life Technologies) and viewed under UV
light for visualisation of the restriction patterns. Determination of the causative Leishmania
species was performed by comparing the resulting restriction patterns to those previously pub-
lished [7]. All PCR-RFLPs were accompanied by a positive control consisting of Leishmania
DNA extracted from a clinical isolate of Leishmania tropica which had been previously isolated
into culture in the Department of Microbiology lab at St Vincent’s Hospital, Sydney.
Ethics Statement
This retrospective study was approved by the institutional ethics review committee at
St. Vincent’s Hospital, Sydney (HREC reference: LNR /14/SVH/374, SSA reference: LNRSSA/
14/SVH/378) and all patient details were de-identified.
Results
Of the 206 samples submitted to the Department of Microbiology between July 2008 and
March 2014 for investigation of leishmaniasis, Leishmania infection was confirmed in 55 pa-
tients by PCR. The vast majority of PCR confirmed cases were male (n = 41) with only 14 con-
firmed female cases. CL was the most common clinical manifestation (n = 52, 94%) with VL in
three patients (5%). Travel to Leishmania endemic regions was the source of infection in most
cases. Patients consisted of 5 defence force personnel who had toured in an endemic country as
part of their duties, 28 people who had travelled overseas for holiday or to visit family in an en-
demic area and 21 patients who had immigrated to Australia from an endemic country. For
two patients who had a history of travel or who had immigrated to Australia, the exact region
in which they had lived or travelled was not specified. A history of travel or residence in Af-
ghanistan was noted in the majority of cases (n = 24) while 13 patients reported travel or resi-
dence in other Middle Eastern countries. There were nine patients that had reportedly travelled
in Central or South America and four patients who had travelled to countries in the Mediterra-
nean, two of whom acquired their infection from Southern Spain. Five species of Leishmania/
Leishmania complex organisms were identified; 30 L. tropica, 7 L. donovanii complex, 5 L. bra-
ziliensis complex, 6 L.major and 2 L.mexicana. For five specimens, speciation could not be de-
termined due to the presence of a very weak positive PCR product resulting in a restriction
pattern that was difficult to interpret. Most patients acquired leishmaniasis in the Old World
(n = 43). For patients with CL, ulcerative lesions on the legs (n = 14) and arms (n = 12) were
the most common manifestations. One patient who was affected by VL acquired their infection
by transplacental transmission. The patient’s mother was a Sudanese refugee who had been liv-
ing in Australia for two years prior to becoming pregnant. This patient died from infection at 2
years old. No cases of MCL were identified in this study. A summary of these results can be
found in Table 1. Fig. 1 shows the digestion of amplified ITS1 regions with the restriction endo-
nuclease HaeIII of different species of Leishmania from isolates from this study on a 4%
agarose gel.
Discussion
Whilst previous cases of imported leishmaniasis have been described, this is the largest series
to examine the molecular epidemiology of imported leishmaniasis in Australia. One previous
Australian study describes a case in a patient who acquired leishmaniasis during travel to Belize
[19]. Another describes an imported case involving an 18 year old male who developed VL
after a trip to Greece [18]. A third report describes four Afghani refugees who were diagnosed
Leishmaniasis in Australia
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Table 1. Patient details, associated risk factor, clinical presentation (site if known) and species identiﬁed.
Patient Age Sex Risk Factor Country Clinical presentation Leishmania species (identiﬁed by RFLP)
1 67 M Travel Peru CL (plaques on chest) L. mexicana
2 39 M Travel Mexico CL (elbow) L. mexicana
3 28 F Travel Costa Rica CL L. braziliensis complex
4 61 F Travel Peru CL (cheek) L. braziliensis complex
5 30 F Travel Colombia CL L. braziliensis complex
6 29 F Travel French Guyana CL (elbow) L. braziliensis complex
7 52 M Travel Colombia CL (calf) L. braziliensis complex
8 2 M Trans placental Australia (Sudan) VL L. donovanii complex
9 69 F Travel Asia, Africa, South America VL L. donovanii complex
10 48 M Travel Southern Spain VL L. donovanii complex
11 60 M Travel Malta CL (buttock) L. donovanii complex
12 54 M Travel Asia, Africa, South America CL (leg) L. donovanii complex
13 40 M Travel Southern Spain CL (calf) L. donovanii complex
14 76 M Immigrant Italy (lived in Australia for 30 yrs) CL L. donovanii complex
15 42 M Immigrant Middle East CL (elbow) L. major
16 24 M Immigrant Afghanistan CL (foot) L. major
17 36 M Travel Afghanistan CL (arm) L. major
18 31 M Army Iraq CL L. major
19 21 M Army Iraq CL L. major
20 31 M Army Syria CL (back) L. major
21 33 M Army Afghanistan CL L. tropica
22 23 M Army Afghanistan CL L. tropica
23 18 M Travel Syria, Iraq CL (arm) L. tropica
24 36 M Travel Middle East CL L. tropica
25 43 F Travel Middle East CL (elbow) L. tropica
26 5 M Travel Middle East CL (foot) L. tropica
27 49 F Travel Middle East CL (foot) L. tropica
28 5 M Travel Middle East CL L. tropica
29 22 M Travel Middle East CL L. tropica
30 66 F Travel Iran CL (face) L. tropica
31 8 F Travel Afghanistan CL L. tropica
32 26 F Travel Afghanistan CL L. tropica
33 12 M Travel Afghanistan CL (cheek) L. tropica
34 20 M Immigrant Afghanistan CL L. tropica
35 23 M Immigrant Afghanistan CL L. tropica
36 69 F Immigrant Afghanistan CL L. tropica
37 2 M Immigrant Afghanistan CL L. tropica
38 2 M Immigrant Afghanistan CL (cheek) L. tropica
39 45 M Immigrant Afghanistan CL (hand) L. tropica
40 26 M Immigrant Afghanistan CL (arm) L. tropica
41 16 M Immigrant Afghanistan CL L. tropica
42 27 M Immigrant Afghanistan CL (leg) L. tropica
43 18 M Immigrant Afghanistan CL (ankle) L. tropica
44 30 M Immigrant Afghanistan CL (thumb) L. tropica
45 30 M Immigrant Afghanistan CL (ﬁnger) L. tropica
46 36 M Immigrant Afghanistan CL (groin) L. tropica
(Continued)
Leishmaniasis in Australia
PLOS ONE | DOI:10.1371/journal.pone.0119212 March 3, 2015 4 / 11
with CL following entry into Australia [20]. The second largest Australian study to date de-
scribed 20 cases of imported leishmaniasis diagnosed over a three year period [16]. The present
study provides the most recent update and reports a further 55 cases of leishmaniasis diagnosed
over a six year period. This study also provides information on the causative species based on
the results of a PCR-RFLP technique previously described [7,21]. Leishmania tropica was the
Table 1. (Continued)
Patient Age Sex Risk Factor Country Clinical presentation Leishmania species (identiﬁed by RFLP)
47 16 M Immigrant Afghanistan CL (ear) L. tropica
48 36 F Immigrant Afghanistan CL (arm) L. tropica
49 18 M Immigrant Afghanistan CL (arm) L. tropica
50 1 M Immigrant Afghanistan CL (ankle) L. tropica
51 28 M Travel Pakistan CL (nose) No ID*
52 36 F Travel Panama CL No ID*
53 26 F Travel Peru CL (arm) No ID*
54 34 M Travel - CL (calf) No ID*
55 26 M Immigrant - CL No ID*
*Due to a very weak PCR positive result which made restriction patterns difﬁcult to interpret
doi:10.1371/journal.pone.0119212.t001
Fig 1. Digestion of amplified ITS1 regions with the restriction endonucleaseHaeIII of different species
of Leishmania from isolates from this study on a 4% agarose gel. Lane 1: L. tropica, lane 2: L.major,
lane 3: L. donovani complex, lane 4: L. braziliensis complex, lane 5: L.mexicana. A 100bp ladder was used as
the molecular size marker (M).
doi:10.1371/journal.pone.0119212.g001
Leishmaniasis in Australia
PLOS ONE | DOI:10.1371/journal.pone.0119212 March 3, 2015 5 / 11
most common species identified in this study (55%) which is higher than the previous Austra-
lian study which reported L. tropica in only 35% of cases [16]. The slight increase in imported
L. tropica infections in comparison to the previous study is probably attributable to the recent
increase in immigration from Afghanistan to Australia and the deployment of defence person-
nel to Afghanistan. In the previous Australian study [16] members of the L. braziliensis com-
plex were the second most common cause of leishmaniasis, in contrast to the present study in
which L. donovanii complex cases were the second most common (n = 7). The proportion of
imported L.major and L.mexicana cases reported in this study is similar to those reported in
the previous Australian study [16].
In the present study, CL was the most common clinical syndrome described (n = 52). Ulcers
on the arms and legs were the most common manifestation in CL patients. Consequently, cuta-
neous lesions on the limbs of travellers returning from endemic Leishmania regions should im-
mediately alert clinicians to the possibility of Leishmania infection. Unsurprisingly, no cases of
MCL were observed in this study, which is in agreement with previous reports of imported
leishmaniasis. Whilst MCL is the most disfiguring of the three Leishmania syndromes, it is also
the least common [3]. MCL usually occurs as a result of infections with NewWorld Leishmania
species (usually Leishmania braziliensis complex) and generally occurs concurrently with or
following a cutaneous infection, albeit rarely [3].
Leishmania tropica was the most common species identified in the study cohort which coin-
cides with the patients' travel history where more than half of the patients had a history of trav-
el to or immigration from Afghanistan or the Middle East. A report from the Netherlands
described L.major as the most common species identified in a cohort consisting predominant-
ly of Dutch soldiers who had been deployed to Afghanistan [5]. In our study it was observed
that three of the five defence personnel were also infected with L.major. In addition, in the
Dutch study L. tropica was only identified in civilians that had a history of travel or residence
in Afghanistan [5]. Most of the cohort examined in this study were infected with L. tropica and
it should be noted that the vast majority were civilian immigrants from Afghanistan. L.major
is commonly found in rural areas whereas L. tropica is predominantly found in urban areas.
This could explain the difference in species found in people who had travelled from the same
country as defence personnel are more likely to be deployed to rural areas and therefore more
likely to be infected with L.major.
In total we were able to identify 25 other series [5,7,16,22–41] reporting three or more cases
of imported leishmaniasis which also included demographic and travel history together with
speciation of isolates, summarised in S1 Table (S1 Published series of travel related leishmania-
sis). Similar to our study most imported cases tend to occur in men, presumably due to risk
taking behaviour, and present as the cutaneous form of the disease. In contrast, NewWorld
species were much less common in our study and the Old World species were mostly acquired
in the Middle East rather than Southern Europe. In a study from the UK, the majority of Old
World leishmaniasis cases were reportedly acquired whilst travelling in Southern Europe [41].
There were only three patients in the present study who acquired their infection after travel to
a Southern European country (Malta and Spain) and a fourth patient from this study is as-
sumed to have acquired their infection in Southern Europe as they had immigrated to Australia
from Italy 30 years prior. These differences are likely explained by the differences in travel pat-
terns of Australian residents and the large number of immigrants in the study. Deployment of
Australian troops to the Middle East during this period likely contributed as well.
A recent report by Alvar et al. describes 98 countries endemic for leishmaniasis from five
continents [6]. Of these, Afghanistan, Colombia, Syria, Peru and Sudan were among the top 10
countries described as having the highest incidence of CL. Not surprisingly, 33 of the 55 pa-
tients from this study acquired their infection in one of these five countries. Due to increased
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global travel, immigration and deployment of defence personnel to Leishmania endemic areas
there is an increased need for clinicians in non-endemic areas to be more aware of leishmania-
sis and to consider it in patients displaying clinical manifestations resembling those of CL, VL
or MCL. Furthermore, clinicians should also be aware that in rare cases, paediatric VL can
occur in patients with no history of travel. In these unusual cases, the familial history should
also be considered given the potential for transplacental transmission of Leishmania to occur
as observed once in this study.
Accurate speciation in clinical cases of leishmaniasis is not only important from an epidemi-
ological perspective, but can be important for predicting the clinical outcome and selecting an
appropriate treatment regimen. NewWorld leishmaniasis caused by species within the L. bra-
ziliensis complex (L. braziliensis, L. guyanensis, L. panamensis and L. peruviana) are more likely
to lead to secondary MCL than other NewWorld species. As MCL can occur up to two years
after cutaneous lesions resolve [42], knowledge of the causative species can facilitate diagnosis
should lesions appear on the mucous membranes at a later time. Furthermore, L. braziliensis
complex organisms are resistant to miltefosine while other species are not [14], so miltefosine
is unlikely to be effective in such cases.
PCR is currently the tool of choice for diagnosis of leishmaniasis. Traditionally microscopy,
histopathology and culture were used though these techniques do not differentiate between
Leishmania species. Prior to the advent of PCR, isoenzyme analysis was the gold standard for
speciation of Leishmania sp. though this technique is comparatively laborious and requires
prior cultivation of parasites in vitro [7]. Several PCR-based tools have been developed which
are capable of differentiating between certain species and/or complexes of Leishmania, though
each of these has its advantages and limitations [7,43–46]. One study showed that Kinetoplast
DNA (kDNA) had the highest sensitivity for the detection of Leishmania sp. over ITS1 PCR
and splice leader mini-exon PCR, however this technique does not allow for speciation [47].
RT-PCRs have been developed but most have the limitation of only differentiating to complex
level and not having the ability to speciate within that complex. The advantage of this though is
that RT-PCR is much faster than conventional PCR, which has to be followed by either RFLP
or sequencing for any kind of speciation, if only the complex level is desired. Generally PCR is
highly sensitive and when coupled with RFLP analysis, the assay employed in this study, can
differentiate between most Leishmania species. This PCR-RFLP does have its limitations how-
ever, as it cannot differentiate between species within the L. donovani complex (L. donovani
and L. infantum/L. chagasi) and those within the L. braziliensis complex. Sequencing of PCR
products to differentiate between species is also complicated by the heterogenous nature of
Leishmania ITS1 sequences. The ribosomal RNA (rRNA) genes exist in eukaryotic genomes as
tandem repeats with many copies [48,49]. In some protozoa (e.g. Toxoplasma gondii and rela-
tives), the ITS1 region is identical for each copy [50,51], which is conducive to sequencing. In
contrast, the ITS1 region in individual Leishmania isolates varies greatly between copies [52].
As a result, PCR products derived from the ITS1 of Leishmania do not produce a clean se-
quencing read. Regardless, because the rRNA genes exist in multiple copies in the genome,
there is still the benefit of increased sensitivity for PCRs targeting these genes compared to
those targeting single copy genes.
There have been no confirmed cases of locally acquired human leishmaniasis in Australia to
date. However, a recent report describes naturally acquired cases of CL in Australian native
macropods including the red kangaroo, the black wallaroo and the agile wallaby [53]. A genetic
characterisation of the causative Leishmania species suggests it is a unique species that is prob-
ably endemic to Australia. While Leishmania DNA has never been detected in Australian spe-
cies of the phlebotamine sand-fly, these Australian Leishmania parasites were recently detected
in a previously undescribed species of day-feeding midge from the subgenus Forcipomyia
Leishmaniasis in Australia
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(Lasiohelea) [10]. While there is little evidence to suggest that this macropod-infecting Leish-
mania sp. can infect humans, the possibility that the Australian midge vector could transmit
pathogenic Leishmania sp. is a cause for concern. In a recent study, midges of the genus Culi-
coides (family Ceratopogonidae) were found to support the replication of Leishmania infantum
and Leishmania major in their midgut for at least 3 days following an experimental infection
[54,55]. Considering that the proposed Australian Leishmania vector is also a member of the
family Ceratopogonidae, it is not unreasonable to suggest that this native midge may also be ca-
pable of transiently supporting the growth of clinically important Leishmania sp.. With cases
of imported human leishmaniasis becoming a regular occurrence in Australia, it is possible
that the native midge vector will come into contact with human infecting Leishmania species,
providing an opportunity for the establishment of a local transmission cycle. While the
support for such an event is limited, it is not unprecedented and certainly warrants continued
investigation.
Conclusion
This represents the largest study to examine the molecular epidemiology of imported leish-
maniasis in Australia. Of 206 patients suspected of harbouring a Leishmania infection over a
six-year period, 55 were confirmed by PCR. The majority of infected patients had travelled to
or immigrated from Afghanistan and L. tropica was the most common species identified.
These results indicate that imported cases of leishmaniasis are an ongoing occurrence in Aus-
tralia and highlights the need for Australian clinicians to consider leishmaniasis when assessing
patients with a history of travel to or residence in endemic regions presenting with Leishman-
ia-associated clinical manifestations.
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